LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $9.00 Average PT from Brokerages

LifeStance Health Group, Inc. (NASDAQ:LFST) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.6667.

Several equities research analysts have issued reports on LFST shares. Weiss Ratings upgraded LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday. Canaccord Genuity Group raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. Barclays began coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, UBS Group boosted their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday.

LifeStance Health Group Stock Performance

LifeStance Health Group stock opened at $7.24 on Friday. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of 362.18 and a beta of 1.12. The firm’s fifty day moving average price is $7.13 and its 200 day moving average price is $6.21.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.02). LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. The business had revenue of $382.20 million for the quarter, compared to analyst estimates of $378.51 million. During the same quarter in the prior year, the business earned ($0.01) earnings per share. The firm’s revenue was up 17.4% on a year-over-year basis. On average, research analysts forecast that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

LifeStance Health Group declared that its board has approved a share repurchase program on Wednesday, February 25th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to buy up to 3.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the sale, the insider directly owned 315,610 shares in the company, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 270,086 shares of company stock valued at $1,891,264 over the last quarter. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of LFST. Larson Financial Group LLC lifted its holdings in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in LifeStance Health Group in the second quarter worth $52,000. Krane Funds Advisors LLC bought a new stake in LifeStance Health Group in the fourth quarter valued at $71,000. Vanguard Personalized Indexing Management LLC bought a new stake in LifeStance Health Group in the third quarter valued at $72,000. Finally, Cibc World Markets Corp acquired a new position in shares of LifeStance Health Group during the fourth quarter valued at $77,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.